- Home
- BLIN vs BLRX Comparison
BLIN vs BLRX Comparison
Compare BLIN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIN
- BLRX
- Stock Information
- Founded
- BLIN 2000
- BLRX 2003
- Country
- BLIN United States
- BLRX Israel
- Employees
- BLIN N/A
- BLRX N/A
- Industry
- BLIN EDP Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BLIN Technology
- BLRX Health Care
- Exchange
- BLIN Nasdaq
- BLRX Nasdaq
- Market Cap
- BLIN 15.0M
- BLRX 12.2M
- IPO Year
- BLIN 2007
- BLRX 2011
- Fundamental
- Price
- BLIN $1.51
- BLRX $2.71
- Analyst Decision
- BLIN Strong Buy
- BLRX Buy
- Analyst Count
- BLIN 1
- BLRX 2
- Target Price
- BLIN $4.62
- BLRX $26.00
- AVG Volume (30 Days)
- BLIN 71.4K
- BLRX 26.6K
- Earning Date
- BLIN 05-13-2025
- BLRX 05-27-2025
- Dividend Yield
- BLIN N/A
- BLRX N/A
- EPS Growth
- BLIN N/A
- BLRX N/A
- EPS
- BLIN N/A
- BLRX N/A
- Revenue
- BLIN $15,394,000.00
- BLRX $28,940,000.00
- Revenue This Year
- BLIN $7.71
- BLRX N/A
- Revenue Next Year
- BLIN $6.98
- BLRX N/A
- P/E Ratio
- BLIN N/A
- BLRX N/A
- Revenue Growth
- BLIN N/A
- BLRX 502.92
- 52 Week Low
- BLIN $0.76
- BLRX $2.85
- 52 Week High
- BLIN $2.80
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- BLIN 59.68
- BLRX 35.52
- Support Level
- BLIN $1.36
- BLRX $3.01
- Resistance Level
- BLIN $2.16
- BLRX $3.61
- Average True Range (ATR)
- BLIN 0.16
- BLRX 0.20
- MACD
- BLIN 0.05
- BLRX 0.00
- Stochastic Oscillator
- BLIN 46.25
- BLRX 0.00
About BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.